Edition:
India

Five Prime Therapeutics Inc (FPRX.OQ)

FPRX.OQ on NASDAQ Stock Exchange Global Select Market

23.61USD
11 Dec 2017
Change (% chg)

$0.75 (+3.28%)
Prev Close
$22.86
Open
$23.01
Day's High
$24.82
Day's Low
$23.01
Volume
330,567
Avg. Vol
185,271
52-wk High
$53.89
52-wk Low
$21.41

Select another date:

Thu, Nov 9 2017

BRIEF-Bristol-Myers and Five Prime present early-stage data evaluating Cabiralizumab with Opdivo in patients with advanced solid tumors

* Bristol-Myers Squibb and Five Prime present phase 1a/1b data evaluating Cabiralizumab (anti-csf-1 receptor antibody) with Opdivo (nivolumab) in patients with advanced solid tumors

BRIEF-Five Prime posts Q3 loss of $1.54 per share

* Five prime announces third quarter 2017 results and provides business update

BRIEF-Five Prime Therapeutics appoints Aron Knickerbocker as CEO

* Five Prime Therapeutics announces appointment of Aron Knickerbocker as CEO effective January 1, 2018

BRIEF-Five Prime to feature two oral data presentations at ESMO congress

* Five Prime to feature two oral data presentations at ESMO 2017 congress Source text for Eikon: Further company coverage:

BRIEF-Five Prime Therapeutics delivered to Inhibrx written notice of termination of agreement

* ‍Pursuant to terms of agreement, termination of agreement will become effective on december 27, 2017 (not 'december 27, 201')​

BRIEF-Five Prime Therapeutics Q2 loss per share $1.58

* Five Prime announces second quarter 2017 results and provides business update

BRIEF-Five Prime Therapeutics plans to initiate a global pivotal trial of FPA144 in 2018

* Five prime Therapeutics initiates patient dosing in phase 1 clinical safety trial evaluating FPA144 in gastric cancer in Japan in preparation for future global late-stage development

BRIEF-Five Prime Therapeutics says Lewis Williams to be chairman of board in 2018

* Five Prime Therapeutics announces Lewis T. "Rusty" Williams plans to transition from CEO to executive chairman of the board in 2018

Select another date: